Lonza to Highlight New ScreenLight™ Block at In-Cosmetics Latin America


South Plainfield, NJ (USA) - 28 August 2018
At In-Cosmetics Latin America, Lonza will feature its new Bioactive Functional ingredient, ScreenLight™ Block, which helps protect skin against the visible effects of blue light, UV light and pollution. In-Cosmetics Latin America will take place 19-20 September in São Paulo (BR). Lonza will be at Stand E30.

ScreenLight™ Block provides a powerful defensive shield against the visible skin aging effects of blue light and more,” said Vanessa Arruda, PhD, Global Market Development Manager, Bioactives. “Consumers who use their cell phones and computers extensively can apply facial creams that not only mitigate the visible effects of the blue light emanating from their screens, but also help protect their skin against the effects of UV stress and pollution."

Key Attributes
The recently launched ScreenLight™ Block helps protect skin against the visible effects of environmental stress factors in a number of ways. It:
  • Helps reduce the appearance of dark spots, resulting in skin that appears more evenly toned (based on in vivo clinical data);
  • Helps reduce the appearance of fine lines and wrinkles (based on subjects’ perceptions of themselves);
  • Helps prevent increased melanin production from exposure to visible light and pollution (based on ex vivo data); and
  • Helps protect skin against the visible effects of light exposure by reducing the negative impact on cellular antioxidant potential (measured by superoxide dismutase, or SOD, expression); elastin, fibrillin, microfibrillar-associated protein 4 (MFAP4) and metalloproteinase-1 (MMP-1, based on ex vivo & in vitro data).
Arruda noted that environmental stressors can degrade unprotected skin and reduce the availability of MFAP4, fibrillin and elastin, leading to loss of elasticity, skin photoaging, worsening wrinkles, fine lines and hyperpigmentation.

Third-party in vitro testing showed that ScreenLight™ Block acts differently under different stress conditions. Under visible light and under conditions of artificial pollution, the bioactive decreases melanin synthesis in the skin. Under UV stress ScreenLight™ Block protects collagen and increases skin elasticity. Clinical trial results showed that ScreenLight™ Block helps reduce the appearance of dark spots, resulting in skin that appears more evenly toned, and helps reduce the appearance of fine lines and wrinkles.

Cutting-Edge Extraction Technology
Lonza produces the ScreenLight™ Block by using cuttingedge Supercritical CO2 extraction, a more environmentally friendly process than traditional extraction techniques. The Physalis alkekengi extract, from a subtropical fruit better known as Chinese Lantern and rich in phytosterols, is obtained by the Supercritical CO2 process. Beta carotene is obtained by the fermenting fungus Blakeslea trispora.

Arruda said ScreenLight™ Block is particularly relevant for those who understand that environmental stress factors may negatively affect their skin. She said ScreenLight™ Block is appropriate for such skin care formulations as facial cream and after-shave lotion, for make-up and for gentle cosmetic formulations.

About Lonza Consumer Product Ingredients – Personal Care
Part of Lonza’s Consumer Product Ingredients business unit, the Personal Care business is a world’s leading supplier of active antidandruff agents, with its Zinc Omadine® product considered the gold standard in the antidandruff shampoo market. Lonza Personal Care also supplies a wide array of other hair- and skin-care products, including biotechnology-derived active ingredients, preservatives for use in certified natural and organic products, specialty esters, functional ingredients and more. More information about these products can be found at www.lonza.com/personalcare.

About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment.

Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.

Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fastmoving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.

Founded in 1897 in the Swiss Alps, Lonza today is a wellrespected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com.

« back